Cargando…
Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice
Background: Immune checkpoint inhibitors have transformed clinical oncology. However, their use is limited as response is observed in only ~20–50% of patients. Previously, we demonstrated that treating CT26 tumor-bearing mice with ultra-high-concentration gaseous nitric oxide (UNO) followed by tumor...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605471/ https://www.ncbi.nlm.nih.gov/pubmed/37887283 http://dx.doi.org/10.3390/cells12202439 |
_version_ | 1785127082360045568 |
---|---|
author | Confino, Hila Sela, Yogev Epshtein, Yana Malka, Lidor Goldshtein, Matan Chaisson, Selena Lisi, Steve Avniel, Amir Monson, Jedidiah Mercer Dirbas, Frederick M. |
author_facet | Confino, Hila Sela, Yogev Epshtein, Yana Malka, Lidor Goldshtein, Matan Chaisson, Selena Lisi, Steve Avniel, Amir Monson, Jedidiah Mercer Dirbas, Frederick M. |
author_sort | Confino, Hila |
collection | PubMed |
description | Background: Immune checkpoint inhibitors have transformed clinical oncology. However, their use is limited as response is observed in only ~20–50% of patients. Previously, we demonstrated that treating CT26 tumor-bearing mice with ultra-high-concentration gaseous nitric oxide (UNO) followed by tumor resection stimulated antitumor immune responses. Accordingly, UNO may improve tumor response to immune checkpoint inhibitors. Here, we investigated the ability of UNO to improve the efficacy of a programmed cell death protein-1 (PD-1) antibody in vitro and in treating CT26 tumor-bearing mice. Methods: CT26 cells were injected into the flank of Balb/c mice (n = 15–16 per group). On day 6, CT26 cells were injected into the contralateral flank, and anti-mPD-1 injections commenced. Primary tumors were treated with intratumoral UNO on day 8. Tumor volume, response rates, toxicity, and survival were monitored. Results: (1) Short exposure to 25,000–100,000 parts per million (ppm) UNO in vitro resulted in significant upregulation of PD-L1 expression on CT26 cells. (2) UNO treatment in vivo consistently reduced cell viability in CT26 tumors. (3) Treatment reduced regulatory T-cell (Treg) levels in the tumor and increased levels of systemic M1 macrophages. UNO responders had increased CD8+ T-cell tumor infiltration. (4) Nine days after treatment, primary tumor growth was significantly lower in the combination arm vs. anti-mPD-1 alone (p = 0.0005). (5) Complete tumor regression occurred in 8/15 (53%) of mice treated with a combination of 10 min UNO and anti-mPD-1, 100 days post-treatment, compared to 4/16 (25%) of controls treated with anti-mPD-1 alone (p = 0.1489). (6) There was no toxicity associated with UNO treatment. (7) Combination treatment showed a trend toward increased survival 100 days post-treatment compared to anti-mPD-1 alone (p = 0.0653). Conclusion: Combining high-concentration NO and immune checkpoint inhibitors warrants further assessment especially in tumors resistant to checkpoint inhibitor therapy. |
format | Online Article Text |
id | pubmed-10605471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106054712023-10-28 Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice Confino, Hila Sela, Yogev Epshtein, Yana Malka, Lidor Goldshtein, Matan Chaisson, Selena Lisi, Steve Avniel, Amir Monson, Jedidiah Mercer Dirbas, Frederick M. Cells Article Background: Immune checkpoint inhibitors have transformed clinical oncology. However, their use is limited as response is observed in only ~20–50% of patients. Previously, we demonstrated that treating CT26 tumor-bearing mice with ultra-high-concentration gaseous nitric oxide (UNO) followed by tumor resection stimulated antitumor immune responses. Accordingly, UNO may improve tumor response to immune checkpoint inhibitors. Here, we investigated the ability of UNO to improve the efficacy of a programmed cell death protein-1 (PD-1) antibody in vitro and in treating CT26 tumor-bearing mice. Methods: CT26 cells were injected into the flank of Balb/c mice (n = 15–16 per group). On day 6, CT26 cells were injected into the contralateral flank, and anti-mPD-1 injections commenced. Primary tumors were treated with intratumoral UNO on day 8. Tumor volume, response rates, toxicity, and survival were monitored. Results: (1) Short exposure to 25,000–100,000 parts per million (ppm) UNO in vitro resulted in significant upregulation of PD-L1 expression on CT26 cells. (2) UNO treatment in vivo consistently reduced cell viability in CT26 tumors. (3) Treatment reduced regulatory T-cell (Treg) levels in the tumor and increased levels of systemic M1 macrophages. UNO responders had increased CD8+ T-cell tumor infiltration. (4) Nine days after treatment, primary tumor growth was significantly lower in the combination arm vs. anti-mPD-1 alone (p = 0.0005). (5) Complete tumor regression occurred in 8/15 (53%) of mice treated with a combination of 10 min UNO and anti-mPD-1, 100 days post-treatment, compared to 4/16 (25%) of controls treated with anti-mPD-1 alone (p = 0.1489). (6) There was no toxicity associated with UNO treatment. (7) Combination treatment showed a trend toward increased survival 100 days post-treatment compared to anti-mPD-1 alone (p = 0.0653). Conclusion: Combining high-concentration NO and immune checkpoint inhibitors warrants further assessment especially in tumors resistant to checkpoint inhibitor therapy. MDPI 2023-10-11 /pmc/articles/PMC10605471/ /pubmed/37887283 http://dx.doi.org/10.3390/cells12202439 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Confino, Hila Sela, Yogev Epshtein, Yana Malka, Lidor Goldshtein, Matan Chaisson, Selena Lisi, Steve Avniel, Amir Monson, Jedidiah Mercer Dirbas, Frederick M. Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice |
title | Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice |
title_full | Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice |
title_fullStr | Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice |
title_full_unstemmed | Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice |
title_short | Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice |
title_sort | intratumoral administration of high-concentration nitric oxide and anti-mpd-1 treatment improves tumor regression rates and survival in ct26 tumor-bearing mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605471/ https://www.ncbi.nlm.nih.gov/pubmed/37887283 http://dx.doi.org/10.3390/cells12202439 |
work_keys_str_mv | AT confinohila intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice AT selayogev intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice AT epshteinyana intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice AT malkalidor intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice AT goldshteinmatan intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice AT chaissonselena intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice AT lisisteve intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice AT avnielamir intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice AT monsonjedidiahmercer intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice AT dirbasfrederickm intratumoraladministrationofhighconcentrationnitricoxideandantimpd1treatmentimprovestumorregressionratesandsurvivalinct26tumorbearingmice |